NCT03205046终止1 期
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Number of Participants With Treatment-Emergent Adverse Events (AEs)
研究概览
简要总结
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by The World Health Organization (WHO):
- •If a subject has de novo DLBCL, the diagnosis is confirmed by biopsy and is immunohistologically characterized as de novo germinal center B-cell-like (GCB) DLBCL or de novo non-GCB DLBCL.
- •If the subjects has Richter's Syndrome (RS), the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL.
- •If the subjects has transformed DLBCL, the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL from indolent lymphoma (eg, follicular lymphoma).
- •Men and women ≥18 years of age.
- •Prior treatment for lymphoid malignancy:
- •If the subject has DLBCL, there is no curative option with conventional therapy and the prior treatment included ≥ 1 prior combination chemoimmunotherapy regimen.
- •If the subject has RS, the subject must have had ≥1 prior treatment with a combination chemoimmunotherapy regimen.
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤
- •Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of a ≥1.5 cm lesion, as measured in the longest dimension by computed tomography [CT] scan).
排除标准
- •As judged by the Investigator, any evidence of severe or uncontrolled systemic disease (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses (eg, hemophilia or von Willebrand disease) or uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug.
- •Diagnosis of PMBCL.
- •Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
- •History of central nervous system (CNS) lymphoma, leptomeningeal disease or spinal cord compression.
- •Any clinically significant pre-existing severe renal disease (eg, glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis) or high risk of developing severe renal impairment.
- •Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] <40% and shortening fraction <15%). Appropriate correction to be used, if a MUGA is performed.
- •Mean resting corrected QT interval (QTc) calculated using Fridericia's formula (QTcF) >450 msec obtained from 3 electrocardiograms (ECGs); family or personal history of long or short QT syndrome; Brugada syndrome or known history of QTc prolongation or torsade de pointes within 12 months of the subject entering the study.
研究组 & 干预措施
Part 1 continuous dose for vistusertib
Experimental
acalabrutinib daily + vistusertib daily
干预措施: acalabrutinib (Drug)
Part 1 continuous dose for vistusertib
Experimental
acalabrutinib daily + vistusertib daily
干预措施: vistusertib (Drug)
Part 1 intermittent dose for vistusertib
Experimental
acalabrutinib daily + vistusertib 5 days on and 2 days off
干预措施: acalabrutinib (Drug)
Part 1 intermittent dose for vistusertib
Experimental
acalabrutinib daily + vistusertib 5 days on and 2 days off
干预措施: vistusertib (Drug)
结局指标
主要结局
Number of Participants With Treatment-Emergent Adverse Events (AEs)
时间窗: From first dose of study drug until 30 days post last dose
Safety assessments comprised type, frequency, severity, and relationship to either or both study drug of any AEs or abnormalities of laboratory tests; serious adverse events (SAEs); dose-limiting toxicities (DLTs); or AEs that led to dose modification, dose delay, or discontinuation of study drug(s).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasRefractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHLDiffuse Large B-cell Lymphoma (DLBCL)De Novo or Transformed Indolent B-cell LymphomaDLBCL, Nos Genetic SubtypesT Cell/Histiocyte-rich Large B-cell LymphomaEBV-Positive DLBCL, NosPrimary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)High-Grade B-Cell Lymphoma, NosC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaGrade 3b Follicular LymphomaC-MYC/BCL2 Double-Hit High-Grade B-Cell LymphomaNCT05583149Patrick C. Johnson, MD28
招募中
2 期
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLDiffuse Large B-Cell LymphomaNCT05952024AstraZeneca80
进行中（未招募）
2 期
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLSmall Lymphocytic LymphomaRelapsed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT04624633Jennifer R. Brown, MD, PhD29
已完成
1 期
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesFollicular Lymphoma (FL)Small Lymphocytic Lymphoma (SLL)Richter's SyndromeMantle Cell Lymphoma (MCL)Indolent Non Hodgkin LymphomaWaldenström MacroglobulinemiaBurkitt LymphomaMarginal Zone LymphomasMediastinal Large B Cell LymphomaHairy Cell LeukemiaHodgkin LymphomaCLLMultiple MyelomaNCT02362035Acerta Pharma BV161
招募中
2 期
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT05336812Ohio State University Comprehensive Cancer Center52